目的 探讨寒喘祖帕颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床疗效。方法 选取2016年2月—2017年2月在玉田县医院进行治疗的哮喘患者113例为研究对象，所有患者根据用药的差别分为对照组（56例）和治疗组（57例）。对照组吸入布地奈德福莫特罗粉吸入剂，初始2吸/次，症状控制后调整为1吸/次，2次/d。治疗组在对照组基础上口服寒喘祖帕颗粒，1袋/次，2次/d。两组患者均治疗1个月。观察两组的临床疗效，比较两组的临床症状消失时间、C反应蛋白（CRP）、炎性因子和肺功能。结果 治疗后，对照组和治疗组的总有效率分别为82.14%、96.49%，两组比较差异具有统计学意义（P < 0.05）。治疗后，治疗组咳嗽消失时间、哮鸣音消失时间、呼吸困难缓解时间均显著短于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组血清CRP、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平均显著降低，同组治疗前后比较差异具有统计学意义（P < 0.05）；且治疗组这些观察指标明显低于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组用力呼气量占用力肺活量比值（FEV1/FVC）、最大呼气流速（PEF）和用力肺活量（FVC）均显著升高，同组治疗前后比较差异有统计学意义（P < 0.05）；且治疗组这些观察指标明显高于对照组，两组比较差异具有统计学意义（P < 0.05）。结论 寒喘祖帕颗粒联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘具有较好的临床疗效，能改善肺功能，缩短临床症状消失时间，调节炎性因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Hanchuan Zupa Granules combined with Budesonide and Formoterol Fumarate Powder for inhalation in treatment of bronchial asthma. Methods Patients (113 cases) with bronchial asthma in Yutian County Hospital from February 2016 to February 2017 were enrolled in this study. According to the difference treatment plan, patients were divided into the control group (56 cases) and the treatment group (57 cases). Patients in the control group were inhalation administered with Budesonide and Formoterol Fumarate Powder for inhalation, initial 2 suctions/time, after symptom control, adjusted to 1 suction/time, once daily. Patients in the treatment group were po administered with Hanchuan Zupa Granules on the basis of the control group, 1 bag/time, once daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the disappearance time of clinical symptoms, the levels of CRP and inflammatory factors, and lung function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.14% and 96.49%, respectively, and there was difference between two groups (P < 0.05). After treatment, coughing disappearance time, wheezing disappearance time, and dyspnea remission time in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the levels of serum CRP, IL-6, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, FEV1/FVC, PEF and FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Hanchuan Zupa Granules combined with Budesonide and Formoterol Fumarate Powder for inhalation has clinical curative effect in treatment of bronchial asthma, can improve lung function, shorten disappearance times of clinical symptoms, and regulate inflammatory factors, which has a certain clinical application value.